These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31449805)

  • 1. Hypnotherapy or medications: a randomized noninferiority trial in urgency urinary incontinent women.
    Komesu YM; Schrader RM; Rogers RG; Sapien RE; Mayer AR; Ketai LH
    Am J Obstet Gynecol; 2020 Feb; 222(2):159.e1-159.e16. PubMed ID: 31449805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mind-body (hypnotherapy) treatment of women with urgency urinary incontinence: changes in brain attentional networks.
    Ketai LH; Komesu YM; Schrader RM; Rogers RG; Sapien RE; Dodd AB; Mayer AR
    Am J Obstet Gynecol; 2021 May; 224(5):498.e1-498.e10. PubMed ID: 33122028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methodology for a trial of brain-centered versus anticholinergic therapy in women with urgency urinary incontinence.
    Komesu YM; Rogers RG; Sapien RE; Schrader RM; Simmerman-Sierra T; Mayer AR; Ketai LH
    Int Urogynecol J; 2017 Jun; 28(6):865-874. PubMed ID: 27752750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women.
    Zimmern P; Litman HJ; Mueller E; Norton P; Goode P;
    BJU Int; 2010 Jun; 105(12):1680-5. PubMed ID: 19912207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
    Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
    Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications.
    Komesu YM; Amundsen CL; Richter HE; Erickson SW; Ackenbom MF; Andy UU; Sung VW; Albo M; Gregory WT; Paraiso MF; Wallace D;
    Am J Obstet Gynecol; 2018 Jan; 218(1):111.e1-111.e9. PubMed ID: 29031894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function.
    Andy UU; Amundsen CL; Honeycutt E; Markland AD; Dunivan G; Dyer KY; Korbly NB; Bradley M; Vasavada S; Mazloomdoost D; Thomas S;
    Am J Obstet Gynecol; 2019 Nov; 221(5):513.e1-513.e15. PubMed ID: 31211964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial.
    Dubeau CE; Kraus SR; Griebling TL; Newman DK; Wyman JF; Johnson TM; Ouslander JG; Sun F; Gong J; Bavendam T
    J Urol; 2014 Feb; 191(2):395-404. PubMed ID: 23973522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).
    Staskin D; Frankel J; Varano S; Shortino D; Jankowich R; Mudd PN
    J Urol; 2021 May; 205(5):1421-1429. PubMed ID: 33356445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TReating Incontinence for Underlying Mental and Physical Health (TRIUMPH): a study protocol for a multicenter, double-blinded, randomized, 3-arm trial to evaluate the multisystem effects of pharmacologic treatment strategies for urgency-predominant urinary incontinence in ambulatory older women.
    Huang AJ; Walter LC; Yaffe K; Vittinghoff E; Kornblith E; Schembri M; Chang A; Subak LL
    Trials; 2023 Apr; 24(1):287. PubMed ID: 37085880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial.
    Burgio KL; Kraus SR; Menefee S; Borello-France D; Corton M; Johnson HW; Mallett V; Norton P; FitzGerald MP; Dandreo KJ; Richter HE; Rozanski T; Albo M; Zyczynski HM; Lemack GE; Chai TC; Khandwala S; Baker J; Brubaker L; Stoddard AM; Goode PS; Nielsen-Omeis B; Nager CW; Kenton K; Tennstedt SL; Kusek JW; Chang TD; Nyberg LM; Steers W;
    Ann Intern Med; 2008 Aug; 149(3):161-9. PubMed ID: 18678843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo.
    Van Kerrebroeck PE; Kelleher CJ; Coyne KS; Kopp Z; Brodsky M; Wang JT
    Health Qual Life Outcomes; 2009 Feb; 7():13. PubMed ID: 19226471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
    Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
    Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electroacupuncture for women with urgency-predominant mixed urinary incontinence: secondary analysis of a randomized noninferiority trial.
    Sun Y; Liu Y; Liu S; Wang W; Liu Z
    World J Urol; 2020 Apr; 38(4):1035-1042. PubMed ID: 31155682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The minimum important difference for the Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire.
    Mamik MM; Rogers RG; Qualls CR; Morrow JD
    Int Urogynecol J; 2014 Oct; 25(10):1321-6. PubMed ID: 24562789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment.
    Ellington DR; Szychowski JM; Malek JM; Gerten KA; Burgio KL; Richter HE
    Female Pelvic Med Reconstr Surg; 2016; 22(4):254-60. PubMed ID: 26945271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women.
    Ayeleke RO; Hay-Smith EJ; Omar MI
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010551. PubMed ID: 26526663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.